<s id="wsj_0404.1"> 38
1 	 0 	 N/N 	 1 	 Inc. Gen-Probe
1 	 7 	 (S[dcl]\NP)/S[dcl] 	 1 	 Inc. said
5 	 3 	 NP[nb]/N 	 1 	 concern a
5 	 4 	 N/N 	 1 	 concern biotechnology
5 	 7 	 (S[dcl]\NP)/S[dcl] 	 1 	 concern said
8 	 9 	 (S[dcl]\NP)/NP 	 1 	 it signed
9 	 7 	 (S[dcl]\NP)/S[dcl] 	 2 	 signed said
12 	 9 	 (S[dcl]\NP)/NP 	 2 	 agreement signed
12 	 10 	 NP[nb]/N 	 1 	 agreement a
12 	 11 	 N/N 	 1 	 agreement definitive
12 	 15 	 (S[pss]\NP)/PP 	 1 	 agreement acquired <XB>
14 	 13 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
15 	 14 	 (S[b]\NP)/(S[pss]\NP) 	 2 	 acquired be
15 	 16 	 ((S\NP)\(S\NP))/NP 	 2 	 acquired by
19 	 16 	 ((S\NP)\(S\NP))/NP 	 3 	 Co. by
19 	 17 	 N/N 	 1 	 Co. Chugai
19 	 18 	 N/N 	 1 	 Co. Pharmaceutical
19 	 20 	 (NP\NP)/NP 	 1 	 Co. of
21 	 20 	 (NP\NP)/NP 	 2 	 Tokyo of
22 	 15 	 (S[pss]\NP)/PP 	 2 	 for acquired
24 	 22 	 PP/NP 	 1 	 $ for
24 	 23 	 N/N 	 1 	 $ about
26 	 24 	 N/N[num] 	 1 	 million $
26 	 25 	 N/N 	 1 	 million 110
30 	 29 	 (NP/NP)/(NP/NP) 	 2 	 double almost
33 	 22 	 PP/NP 	 1 	 price for
33 	 30 	 NP/NP 	 1 	 price double
33 	 31 	 NP[nb]/N 	 1 	 price the
33 	 32 	 N/N 	 1 	 price market
33 	 34 	 (NP\NP)/NP 	 1 	 price of
35 	 36 	 (NP[nb]/N)\NP 	 2 	 Gen-Probe 's
37 	 34 	 (NP\NP)/NP 	 2 	 stock of
37 	 36 	 (NP[nb]/N)\NP 	 1 	 stock 's
<\s>
<s id="wsj_0404.2"> 15
1 	 0 	 NP[nb]/N 	 1 	 move The
1 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 move is
1 	 3 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 move sure <XB>
3 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 sure is
4 	 3 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to sure
5 	 4 	 (S[to]\NP)/(S[b]\NP) 	 2 	 heighten to
6 	 5 	 (S[b]\NP)/NP 	 2 	 concerns heighten
6 	 7 	 (NP\NP)/NP 	 1 	 concerns about
10 	 7 	 (NP\NP)/NP 	 2 	 investment about
10 	 8 	 N/N 	 1 	 investment increased
10 	 9 	 N/N 	 1 	 investment Japanese
10 	 11 	 (NP\NP)/NP 	 1 	 investment in
14 	 11 	 (NP\NP)/NP 	 2 	 firms in
14 	 12 	 N/N 	 1 	 firms U.S.
14 	 13 	 N/N 	 1 	 firms biotechnology
<\s>
<s id="wsj_0404.3"> 25
0 	 1 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 It is
0 	 3 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 It likely <XB>
1 	 2 	 (S\NP)\(S\NP) 	 2 	 is also
3 	 1 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 likely is
4 	 3 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to likely
5 	 4 	 (S[to]\NP)/(S[b]\NP) 	 2 	 bolster to
6 	 5 	 (S[b]\NP)/NP 	 2 	 fears bolster
7 	 6 	 N/S[em] 	 1 	 that fears
9 	 8 	 NP[nb]/N 	 1 	 Japanese the
9 	 10 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Japanese will
9 	 11 	 ((S[b]\NP)/(S[to]\NP))/NP 	 1 	 Japanese use <XB>
10 	 7 	 S[em]/S[dcl] 	 1 	 will that
11 	 10 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 use will
13 	 11 	 ((S[b]\NP)/(S[to]\NP))/NP 	 3 	 foothold use
13 	 12 	 NP[nb]/N 	 1 	 foothold their
13 	 14 	 (NP\NP)/NP 	 1 	 foothold in
13 	 19 	 (S[b]\NP)/NP 	 1 	 foothold gain <XB>
17 	 14 	 (NP\NP)/NP 	 2 	 concerns in
17 	 15 	 N/N 	 1 	 concerns U.S.
17 	 16 	 N/N 	 1 	 concerns biotechnology
18 	 11 	 ((S[b]\NP)/(S[to]\NP))/NP 	 2 	 to use
19 	 18 	 (S[to]\NP)/(S[b]\NP) 	 2 	 gain to
24 	 19 	 (S[b]\NP)/NP 	 2 	 advantages gain
24 	 20 	 N/N 	 1 	 advantages certain
24 	 21 	 N/N 	 1 	 advantages trade <XU>
24 	 23 	 N/N 	 1 	 advantages competitive
<\s>
<s id="wsj_0404.4"> 42
0 	 24 	 (S[dcl]\NP)/NP 	 1 	 Gen-Probe signed
4 	 2 	 NP[nb]/N 	 1 	 leader an
4 	 3 	 N/N 	 1 	 leader industry
4 	 5 	 (NP\NP)/NP 	 1 	 leader in
4 	 24 	 (S[dcl]\NP)/NP 	 1 	 leader signed
7 	 5 	 (NP\NP)/NP 	 2 	 field in
7 	 6 	 NP[nb]/N 	 1 	 field the
7 	 8 	 (NP\NP)/NP 	 1 	 field of
10 	 8 	 (NP\NP)/NP 	 2 	 probes of
10 	 9 	 N/N 	 1 	 probes genetic
10 	 12 	 (NP\NP)/(S[dcl]\NP) 	 1 	 probes which
10 	 13 	 (S[dcl]\NP)/NP 	 1 	 probes is <XB>
13 	 12 	 (NP\NP)/(S[dcl]\NP) 	 2 	 is which
16 	 13 	 (S[dcl]\NP)/NP 	 2 	 technology is
16 	 14 	 NP[nb]/N 	 1 	 technology a
16 	 15 	 N/N 	 1 	 technology new
16 	 17 	 S[pss]\NP 	 1 	 technology used <XB>
17 	 18 	 ((S\NP)\(S\NP))/NP 	 2 	 used in
20 	 18 	 ((S\NP)\(S\NP))/NP 	 3 	 tests in
20 	 19 	 N/N 	 1 	 tests diagnostic
23 	 22 	 ((S\NP)/(S\NP))/((S\NP)/(S\NP)) 	 3 	 year last
24 	 23 	 (S\NP)/(S\NP) 	 2 	 signed year
26 	 24 	 (S[dcl]\NP)/NP 	 2 	 agreement signed
26 	 25 	 NP[nb]/N 	 1 	 agreement an
27 	 26 	 N/S[for] 	 1 	 for agreement
28 	 27 	 (S[for]/(S[to]\NP))/NP 	 2 	 Chugai for
28 	 31 	 (S[b]\NP)/NP 	 1 	 Chugai market <XB>
29 	 27 	 (S[for]/(S[to]\NP))/NP 	 1 	 to for
31 	 29 	 (S[to]\NP)/(S[b]\NP) 	 2 	 market to
31 	 30 	 (S\NP)/(S\NP) 	 2 	 market exclusively
31 	 35 	 ((S\NP)\(S\NP))/NP 	 2 	 market in
31 	 37 	 ((S\NP)\(S\NP))/NP 	 2 	 market for
34 	 31 	 (S[b]\NP)/NP 	 2 	 products market
34 	 32 	 NP[nb]/N 	 1 	 products its
34 	 33 	 N/N 	 1 	 products diagnostic
36 	 35 	 ((S\NP)\(S\NP))/NP 	 3 	 Japan in
39 	 37 	 ((S\NP)\(S\NP))/NP 	 3 	 diseases for
39 	 38 	 N/N 	 1 	 diseases infectious
41 	 37 	 ((S\NP)\(S\NP))/NP 	 3 	 cancer for
<\s>
<s id="wsj_0404.5"> 11
0 	 1 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 Chugai agreed
0 	 4 	 (S[b]\NP)/NP 	 1 	 Chugai fund <XB>
1 	 2 	 (S\NP)\(S\NP) 	 2 	 agreed then
3 	 1 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to agreed
4 	 3 	 (S[to]\NP)/(S[b]\NP) 	 2 	 fund to
10 	 4 	 (S[b]\NP)/NP 	 2 	 costs fund
10 	 5 	 N/N 	 1 	 costs certain
10 	 6 	 N/N 	 1 	 costs associated
10 	 7 	 N/N 	 1 	 costs research
10 	 9 	 N/N 	 1 	 costs development
<\s>
<s id="wsj_0404.6"> 49
1 	 0 	 NP[nb]/N 	 1 	 arrangement That
1 	 3 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 arrangement has
1 	 4 	 S[pt]\NP 	 1 	 arrangement worked <XB>
3 	 2 	 (S\NP)/(S\NP) 	 2 	 has apparently
4 	 3 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 worked has
4 	 5 	 (S\NP)\(S\NP) 	 2 	 worked well
10 	 8 	 N/N 	 1 	 Bologna Thomas
10 	 9 	 N/N 	 1 	 Bologna A.
10 	 24 	 (S[dcl]\NP)/S[dcl] 	 1 	 Bologna said
12 	 17 	 (NP\NP)/NP 	 1 	 president of
12 	 24 	 (S[dcl]\NP)/S[dcl] 	 1 	 president said
16 	 14 	 N/N 	 1 	 officer chief
16 	 15 	 N/N 	 1 	 officer executive
16 	 17 	 (NP\NP)/NP 	 1 	 officer of
16 	 24 	 (S[dcl]\NP)/S[dcl] 	 1 	 officer said
18 	 17 	 (NP\NP)/NP 	 2 	 Gen-Probe of
18 	 20 	 S[pss]\NP 	 1 	 Gen-Probe founded <XB>
20 	 21 	 ((S\NP)\(S\NP))/NP 	 2 	 founded in
22 	 21 	 ((S\NP)\(S\NP))/NP 	 3 	 1983 in
26 	 25 	 NP[nb]/N 	 1 	 sale the
26 	 27 	 (NP\NP)/NP 	 1 	 sale of
26 	 30 	 (S[dcl]\NP)/S[dcl] 	 1 	 sale means
29 	 27 	 (NP\NP)/NP 	 2 	 company of
29 	 28 	 NP[nb]/N 	 1 	 company the
30 	 24 	 (S[dcl]\NP)/S[dcl] 	 2 	 means said
31 	 32 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 we will
31 	 34 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 we able <XB>
32 	 30 	 (S[dcl]\NP)/S[dcl] 	 2 	 will means
33 	 32 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be will
34 	 33 	 (S[b]\NP)/(S[adj]\NP) 	 2 	 able be
35 	 34 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to able
36 	 35 	 (S[to]\NP)/(S[b]\NP) 	 2 	 concentrate to
37 	 36 	 (S[b]\NP)/PP 	 2 	 on concentrate
38 	 37 	 PP/(S[ng]\NP) 	 1 	 running on
40 	 38 	 (S[ng]\NP)/NP 	 2 	 business running
40 	 39 	 NP[nb]/N 	 1 	 business the
42 	 41 	 conj/conj 	 1 	 than rather
44 	 37 	 PP/(S[ng]\NP) 	 1 	 looking on
44 	 43 	 (S\NP)/(S\NP) 	 2 	 looking always
45 	 44 	 (S[ng]\NP)/PP 	 2 	 for looking
46 	 45 	 PP/NP 	 1 	 sources for
46 	 47 	 (NP\NP)/NP 	 1 	 sources of
48 	 47 	 (NP\NP)/NP 	 2 	 financing of
<\s>
<s id="wsj_0404.7"> 21
0 	 1 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 Chugai agreed
0 	 3 	 ((S[b]\NP)/PP)/NP 	 1 	 Chugai pay <XB>
2 	 1 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to agreed
3 	 2 	 (S[to]\NP)/(S[b]\NP) 	 2 	 pay to
3 	 16 	 ((S\NP)\(S\NP))/NP 	 2 	 pay on
4 	 3 	 ((S[b]\NP)/PP)/NP 	 3 	 $ pay
4 	 6 	 (NP\NP)/N 	 1 	 $ a
5 	 4 	 N/N[num] 	 1 	 6.25 $
7 	 6 	 (NP\NP)/N 	 2 	 share a
8 	 3 	 ((S[b]\NP)/PP)/NP 	 2 	 for pay
9 	 10 	 (NP[nb]/N)\NP 	 2 	 Gen-Probe 's
12 	 11 	 (N/N)/(N/N) 	 2 	 million 17.6
14 	 8 	 PP/NP 	 1 	 shares for
14 	 10 	 (NP[nb]/N)\NP 	 1 	 shares 's
14 	 12 	 N/N 	 1 	 shares million
14 	 13 	 N/N 	 1 	 shares common
14 	 15 	 S[adj]\NP 	 1 	 shares outstanding <XB>
19 	 18 	 (N/N)/(N/N) 	 2 	 diluted fully
20 	 16 	 ((S\NP)\(S\NP))/NP 	 3 	 basis on
20 	 17 	 NP[nb]/N 	 1 	 basis a
20 	 19 	 N/N 	 1 	 basis diluted
<\s>
<s id="wsj_0404.8"> 18
4 	 2 	 (S/S)/NP 	 2 	 trading in
4 	 3 	 N/N 	 1 	 trading national
4 	 5 	 (NP\NP)/NP 	 1 	 trading in
8 	 5 	 (NP\NP)/NP 	 2 	 market in
8 	 6 	 NP[nb]/N 	 1 	 market the
8 	 7 	 N/N 	 1 	 market over-the-counter
11 	 10 	 N/N 	 1 	 common Gen-Probe
11 	 12 	 (S[dcl]\NP)/PP 	 1 	 common closed
12 	 0 	 S/S 	 1 	 closed Yesterday
12 	 2 	 (S/S)/NP 	 1 	 closed in
13 	 12 	 (S[dcl]\NP)/PP 	 2 	 at closed
14 	 13 	 PP/NP 	 1 	 $ at
14 	 16 	 (NP\NP)/N 	 1 	 $ a
15 	 14 	 N/N[num] 	 1 	 3.25 $
17 	 16 	 (NP\NP)/N 	 2 	 share a
<\s>
<s id="wsj_0404.9"> 47
2 	 1 	 NP[nb]/N 	 1 	 U.S. the
2 	 3 	 (S[dcl]\NP)/PP 	 1 	 U.S. leads
3 	 0 	 (S/S)/S[dcl] 	 2 	 leads Because
3 	 11 	 ((S\NP)\(S\NP))/PP 	 2 	 leads because
4 	 3 	 (S[dcl]\NP)/PP 	 2 	 in leads
6 	 4 	 PP/NP 	 1 	 areas in
6 	 5 	 N/N 	 1 	 areas most
6 	 7 	 (NP\NP)/NP 	 1 	 areas of
8 	 7 	 (NP\NP)/NP 	 2 	 biotechnology of
11 	 10 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 because largely
12 	 11 	 ((S\NP)\(S\NP))/PP 	 3 	 of because
14 	 12 	 PP/NP 	 1 	 investment of
14 	 13 	 N/N 	 1 	 investment research
14 	 15 	 (NP\NP)/NP 	 1 	 investment by
18 	 15 	 (NP\NP)/NP 	 2 	 government by
18 	 16 	 NP[nb]/N 	 1 	 government the
18 	 17 	 N/N 	 1 	 government U.S.
21 	 20 	 NP[nb]/N 	 1 	 sale the
21 	 22 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 sale is
21 	 23 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 sale sure <XB>
22 	 0 	 (S/S)/S[dcl] 	 1 	 is Because
23 	 22 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 sure is
24 	 23 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to sure
25 	 24 	 (S[to]\NP)/(S[b]\NP) 	 2 	 increase to
26 	 25 	 (S[b]\NP)/NP 	 2 	 concerns increase
27 	 26 	 N/S[em] 	 1 	 that concerns
29 	 28 	 N/N 	 1 	 companies Japanese
29 	 30 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 companies will
29 	 31 	 (S[b]\NP)/NP 	 1 	 companies buy <XB>
29 	 35 	 ((S[b]\NP)/(S[to]\NP))/NP 	 1 	 companies use <XU>
30 	 27 	 S[em]/S[dcl] 	 1 	 will that
31 	 30 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 buy will
33 	 31 	 (S[b]\NP)/NP 	 2 	 know-how buy
33 	 32 	 N/N 	 1 	 know-how American
35 	 30 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 use will
36 	 35 	 ((S[b]\NP)/(S[to]\NP))/NP 	 3 	 it use
36 	 38 	 (S[b]\NP)/NP 	 1 	 it obtain <XB>
37 	 35 	 ((S[b]\NP)/(S[to]\NP))/NP 	 2 	 to use
38 	 37 	 (S[to]\NP)/(S[b]\NP) 	 2 	 obtain to
38 	 42 	 ((S\NP)\(S\NP))/NP 	 2 	 obtain in
41 	 38 	 (S[b]\NP)/NP 	 2 	 hand obtain
41 	 39 	 NP[nb]/N 	 1 	 hand the
41 	 40 	 N/N 	 1 	 hand upper
44 	 42 	 ((S\NP)\(S\NP))/NP 	 3 	 trade in
44 	 43 	 N/N 	 1 	 trade biotechnology
46 	 42 	 ((S\NP)\(S\NP))/NP 	 3 	 competition in
46 	 43 	 N/N 	 1 	 competition biotechnology
<\s>
<s id="wsj_0404.10"> 21
2 	 0 	 NP[nb]/N 	 1 	 firms The
2 	 1 	 N/N 	 1 	 firms biotechnology
2 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 firms may
2 	 5 	 (S[ng]\NP)/NP 	 1 	 firms setting <XB>
3 	 11 	 (S[dcl]\S[dcl])/NP 	 1 	 may said
4 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be may
5 	 4 	 (S[b]\NP)/(S[ng]\NP) 	 2 	 setting be
5 	 6 	 (S\NP)\(S\NP) 	 2 	 setting up
9 	 5 	 (S[ng]\NP)/NP 	 2 	 competitors setting
9 	 7 	 NP[nb]/N 	 1 	 competitors their
9 	 8 	 N/N 	 1 	 competitors own
13 	 11 	 (S[dcl]\S[dcl])/NP 	 2 	 Godown said
13 	 12 	 N/N 	 1 	 Godown Richard
15 	 11 	 (S[dcl]\S[dcl])/NP 	 2 	 president said
15 	 16 	 (NP\NP)/NP 	 1 	 president of
20 	 16 	 (NP\NP)/NP 	 2 	 Association of
20 	 17 	 NP[nb]/N 	 1 	 Association the
20 	 18 	 N/N 	 1 	 Association Industrial
20 	 19 	 N/N 	 1 	 Association Biotechnology
<\s>
<s id="wsj_0404.11"> 16
0 	 1 	 (S[dcl]\NP)/S[em] 	 1 	 He added
2 	 1 	 (S[dcl]\NP)/S[em] 	 2 	 that added
4 	 3 	 (S/S)/(S[adj]\NP) 	 2 	 now until
6 	 5 	 NP[nb]/N 	 1 	 Japanese the
6 	 7 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 Japanese have
6 	 9 	 (S[pt]\NP)/NP 	 1 	 Japanese acquired <XB>
7 	 2 	 S[em]/S[dcl] 	 1 	 have that
7 	 3 	 (S/S)/(S[adj]\NP) 	 1 	 have until
9 	 7 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 acquired have
9 	 8 	 (S\NP)/(S\NP) 	 2 	 acquired only
11 	 9 	 (S[pt]\NP)/NP 	 2 	 positions acquired
11 	 10 	 N/N 	 1 	 positions equity
11 	 12 	 (NP\NP)/NP 	 1 	 positions in
15 	 12 	 (NP\NP)/NP 	 2 	 companies in
15 	 13 	 N/N 	 1 	 companies U.S.
15 	 14 	 N/N 	 1 	 companies biotechnology
<\s>
<s id="wsj_0404.12"> 9
0 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 They are
0 	 2 	 (S[ng]\NP)/PP 	 1 	 They piggybacking <XB>
1 	 8 	 (S[dcl]\S[dcl])\NP 	 1 	 are said
2 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 piggybacking are
3 	 2 	 (S[ng]\NP)/PP 	 2 	 onto piggybacking
5 	 3 	 PP/NP 	 1 	 technology onto
5 	 4 	 N/N 	 1 	 technology developed
7 	 8 	 (S[dcl]\S[dcl])\NP 	 2 	 he said
<\s>
<s id="wsj_0404.13"> 20
4 	 0 	 (S/S)/NP 	 2 	 years During
4 	 1 	 NP[nb]/N 	 1 	 years the
4 	 2 	 N/N 	 1 	 years past
4 	 3 	 N/N 	 1 	 years five
7 	 6 	 N/N 	 1 	 concerns Japanese
7 	 8 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 concerns have
7 	 9 	 (S[pt]\NP)/PP 	 1 	 concerns invested <XB>
8 	 0 	 (S/S)/NP 	 1 	 have During
9 	 8 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 invested have
10 	 9 	 (S[pt]\NP)/PP 	 2 	 in invested
11 	 10 	 PP/NP 	 1 	 several in
11 	 12 	 (NP\NP)/NP 	 1 	 several of
14 	 13 	 NP[nb]/N 	 1 	 U.S. the
14 	 15 	 (NP[nb]/N)\NP 	 2 	 U.S. 's
19 	 12 	 (NP\NP)/NP 	 2 	 companies of
19 	 15 	 (NP[nb]/N)\NP 	 1 	 companies 's
19 	 16 	 N/N 	 1 	 companies 431
19 	 17 	 N/N 	 1 	 companies independent
19 	 18 	 N/N 	 1 	 companies biotechnology
<\s>
<s id="wsj_0404.14"> 40
0 	 1 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 Chugai has
0 	 2 	 (S[pt]\NP)/NP 	 1 	 Chugai been <XB>
2 	 1 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been has
3 	 2 	 (S[pt]\NP)/NP 	 2 	 one been
3 	 4 	 (NP\NP)/NP 	 1 	 one of
7 	 6 	 (N/N)/(N/N) 	 2 	 active most
9 	 4 	 (NP\NP)/NP 	 2 	 players of
9 	 5 	 NP[nb]/N 	 1 	 players the
9 	 7 	 N/N 	 1 	 players active
9 	 8 	 N/N 	 1 	 players Japanese
9 	 10 	 (NP\NP)/NP 	 1 	 players in
13 	 10 	 (NP\NP)/NP 	 2 	 companies in
13 	 11 	 N/N 	 1 	 companies U.S.
13 	 12 	 N/N 	 1 	 companies biotechnology
15 	 16 	 (S[dcl]\NP)/NP 	 1 	 it has
19 	 16 	 (S[dcl]\NP)/NP 	 2 	 investment has
19 	 17 	 NP[nb]/N 	 1 	 investment an
19 	 18 	 N/N 	 1 	 investment equity
19 	 20 	 (NP\NP)/NP 	 1 	 investment in
23 	 20 	 (NP\NP)/NP 	 2 	 Inc. in
23 	 21 	 N/N 	 1 	 Inc. Genetics
23 	 22 	 N/N 	 1 	 Inc. Institute
23 	 25 	 NP\NP 	 1 	 Inc. Cambridge
23 	 27 	 NP\NP 	 1 	 Inc. Mass. <XU>
32 	 16 	 (S[dcl]\NP)/NP 	 2 	 agreement has
32 	 30 	 NP[nb]/N 	 1 	 agreement a
32 	 31 	 N/N 	 1 	 agreement joint-venture
32 	 33 	 (NP\NP)/NP 	 1 	 agreement with
35 	 33 	 (NP\NP)/NP 	 2 	 Co. with
35 	 34 	 N/N 	 1 	 Co. Upjohn
35 	 37 	 NP\NP 	 1 	 Co. Kalamazoo
35 	 39 	 NP\NP 	 1 	 Co. Mich <XU>
<\s>
<s id="wsj_0404.15"> 28
2 	 0 	 NP[nb]/N 	 1 	 government The
2 	 1 	 N/N 	 1 	 government Japanese
2 	 8 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 government has
2 	 9 	 (S[pt]\NP)/S[em] 	 1 	 government stated <XB>
5 	 4 	 N/N 	 1 	 Godown Mr.
5 	 6 	 (S[dcl]\NP)/S[dcl] 	 1 	 Godown said
9 	 8 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 stated has
10 	 9 	 (S[pt]\NP)/S[em] 	 2 	 that stated
11 	 12 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 1 	 it wants
12 	 10 	 S[em]/S[dcl] 	 1 	 wants that
14 	 12 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 3 	 % wants
14 	 13 	 N/N 	 1 	 % 10
14 	 15 	 (N\N)/N 	 1 	 % to
14 	 18 	 (NP\NP)/NP 	 1 	 % of
14 	 24 	 (S[b]\NP)/PP 	 1 	 % come <XB>
17 	 15 	 (N\N)/N 	 2 	 % to
17 	 16 	 N/N 	 1 	 % 11
22 	 18 	 (NP\NP)/NP 	 2 	 product of
22 	 19 	 NP[nb]/N 	 1 	 product its
22 	 20 	 N/N 	 1 	 product gross
22 	 21 	 N/N 	 1 	 product national
23 	 12 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 2 	 to wants
24 	 23 	 (S[to]\NP)/(S[b]\NP) 	 2 	 come to
25 	 24 	 (S[b]\NP)/PP 	 2 	 from come
27 	 25 	 PP/NP 	 1 	 products from
27 	 26 	 N/N 	 1 	 products biotechnology
<\s>
<s id="wsj_0404.16"> 45
0 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 It is
0 	 2 	 (S[ng]\NP)/NP 	 1 	 It becoming <XB>
1 	 17 	 (S[dcl]\S[dcl])\NP 	 1 	 is said
2 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 becoming is
2 	 8 	 ((S\NP)\(S\NP))/N 	 2 	 becoming every
2 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 becoming between
3 	 2 	 (S[ng]\NP)/NP 	 2 	 more becoming
3 	 4 	 (NP\NP)/NP 	 1 	 more of
7 	 4 	 (NP\NP)/NP 	 2 	 race of
7 	 5 	 NP[nb]/N 	 1 	 race a
7 	 6 	 N/N 	 1 	 race horse
9 	 8 	 ((S\NP)\(S\NP))/N 	 3 	 day every
12 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 U.S. between
12 	 11 	 NP[nb]/N 	 1 	 U.S. the
14 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 Japan between
16 	 17 	 (S[dcl]\S[dcl])\NP 	 2 	 he said
20 	 19 	 (S[ng]\NP)/S[em] 	 2 	 that adding
21 	 22 	 (S[dcl]\NP)/S[em] 	 1 	 some fear
22 	 20 	 S[em]/S[dcl] 	 1 	 fear that
23 	 22 	 (S[dcl]\NP)/S[em] 	 2 	 that fear
25 	 24 	 (S/S)/PP 	 2 	 with as
33 	 25 	 PP/NP 	 1 	 industries with
33 	 26 	 NP[nb]/N 	 1 	 industries the
33 	 27 	 N/N 	 1 	 industries semiconductor
33 	 29 	 N/N 	 1 	 industries electronics
33 	 32 	 N/N 	 1 	 industries automobile
36 	 35 	 N/N 	 1 	 companies Japanese
36 	 37 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 companies will
36 	 38 	 ((S[b]\NP)/(S[to]\NP))/NP 	 1 	 companies use <XB>
37 	 23 	 S[em]/S[dcl] 	 1 	 will that
37 	 24 	 (S/S)/PP 	 1 	 will as
38 	 37 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 use will
40 	 38 	 ((S[b]\NP)/(S[to]\NP))/NP 	 3 	 technology use
40 	 39 	 N/N 	 1 	 technology U.S.-developed
40 	 42 	 (S[b]\NP)/NP 	 1 	 technology gain <XB>
41 	 38 	 ((S[b]\NP)/(S[to]\NP))/NP 	 2 	 to use
42 	 41 	 (S[to]\NP)/(S[b]\NP) 	 2 	 gain to
44 	 42 	 (S[b]\NP)/NP 	 2 	 advantages gain
44 	 43 	 N/N 	 1 	 advantages trade
<\s>
<s id="wsj_0404.17"> 35
1 	 0 	 N/N 	 1 	 Bologna Mr.
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Bologna said
4 	 3 	 NP[nb]/N 	 1 	 sale the
4 	 5 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 sale would
4 	 6 	 ((S[b]\NP)/(S[to]\NP))/NP 	 1 	 sale allow <XB>
5 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 would said
6 	 5 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 allow would
7 	 6 	 ((S[b]\NP)/(S[to]\NP))/NP 	 3 	 Gen-Probe allow
7 	 9 	 (S[b]\NP)/NP 	 1 	 Gen-Probe speed <XB>
7 	 21 	 ((S[b]\NP)/PP)/NP 	 1 	 Gen-Probe apply <XU>
8 	 6 	 ((S[b]\NP)/(S[to]\NP))/NP 	 2 	 to allow
9 	 8 	 (S[to]\NP)/(S[b]\NP) 	 2 	 speed to
9 	 10 	 (S\NP)\(S\NP) 	 2 	 speed up
12 	 9 	 (S[b]\NP)/NP 	 2 	 development speed
12 	 11 	 NP[nb]/N 	 1 	 development the
12 	 13 	 (NP\NP)/NP 	 1 	 development of
15 	 13 	 (NP\NP)/NP 	 2 	 technology of
15 	 14 	 N/N 	 1 	 technology new
18 	 6 	 ((S[b]\NP)/(S[to]\NP))/NP 	 2 	 to allow
18 	 20 	 (S\NP)\(S\NP) 	 2 	 to quickly
20 	 19 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 quickly more
21 	 18 	 (S[to]\NP)/(S[b]\NP) 	 2 	 apply to
23 	 21 	 ((S[b]\NP)/PP)/NP 	 3 	 technology apply
23 	 22 	 N/N 	 1 	 technology existing
24 	 21 	 ((S[b]\NP)/PP)/NP 	 2 	 to apply
26 	 24 	 PP/NP 	 1 	 array to
26 	 25 	 NP[nb]/N 	 1 	 array an
26 	 27 	 (NP\NP)/NP 	 1 	 array of
29 	 27 	 (NP\NP)/NP 	 2 	 products of
29 	 28 	 N/N 	 1 	 products diagnostic
29 	 34 	 (S[b]\NP)/NP 	 2 	 products offer <XU>
31 	 30 	 NP[nb]/N 	 1 	 company the
31 	 32 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 company wants
31 	 34 	 (S[b]\NP)/NP 	 1 	 company offer <XB>
33 	 32 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to wants
34 	 33 	 (S[to]\NP)/(S[b]\NP) 	 2 	 offer to
<\s>
<s id="wsj_0404.18"> 37
1 	 0 	 (S/S)/NP 	 2 	 1988 By
1 	 3 	 (NP\NP)/S[dcl] 	 1 	 1988 when
5 	 4 	 (N/N)/(N/N) 	 2 	 10 only
8 	 5 	 N/N 	 1 	 tests 10
8 	 6 	 N/N 	 1 	 tests genetic
8 	 7 	 N/N 	 1 	 tests probe-based
8 	 9 	 (NP\NP)/NP 	 1 	 tests of
8 	 15 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 tests had
8 	 17 	 S[pss]\NP 	 1 	 tests approved <XB>
12 	 9 	 (NP\NP)/NP 	 2 	 diseases of
12 	 10 	 N/N 	 1 	 diseases diagnostic
12 	 11 	 N/N 	 1 	 diseases infectious
12 	 13 	 (NP\NP)/NP 	 1 	 diseases of
14 	 13 	 (NP\NP)/NP 	 2 	 humans of
15 	 3 	 (NP\NP)/S[dcl] 	 2 	 had when
16 	 15 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been had
17 	 16 	 (S[pt]\NP)/(S[pss]\NP) 	 2 	 approved been
17 	 18 	 ((S\NP)\(S\NP))/NP 	 2 	 approved for
17 	 20 	 ((S\NP)\(S\NP))/NP 	 2 	 approved by
19 	 18 	 ((S\NP)\(S\NP))/NP 	 3 	 marketing for
22 	 20 	 ((S\NP)\(S\NP))/NP 	 3 	 Food by
22 	 21 	 NP[nb]/N 	 1 	 Food the
25 	 20 	 ((S\NP)\(S\NP))/NP 	 3 	 Administration by
25 	 21 	 NP[nb]/N 	 1 	 Administration the
25 	 24 	 N/N 	 1 	 Administration Drug
27 	 28 	 (NP\NP)/NP 	 1 	 eight of
27 	 30 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 eight had
27 	 32 	 S[pss]\NP 	 1 	 eight developed <XB>
27 	 34 	 S[pss]\NP 	 1 	 eight sold <XU>
29 	 28 	 (NP\NP)/NP 	 2 	 them of
30 	 0 	 (S/S)/NP 	 1 	 had By
31 	 30 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been had
32 	 31 	 (S[pt]\NP)/(S[pss]\NP) 	 2 	 developed been
32 	 35 	 ((S\NP)\(S\NP))/NP 	 2 	 developed by
34 	 31 	 (S[pt]\NP)/(S[pss]\NP) 	 2 	 sold been
34 	 35 	 ((S\NP)\(S\NP))/NP 	 2 	 sold by
36 	 35 	 ((S\NP)\(S\NP))/NP 	 3 	 Gen-Probe by
<\s>
<s id="wsj_0404.19"> 33
1 	 0 	 N/N 	 1 	 Nagayama Osamu
1 	 21 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 Nagayama was
1 	 22 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 Nagayama unable <XB>
4 	 3 	 N/N 	 1 	 president deputy
4 	 5 	 (NP\NP)/NP 	 1 	 president of
4 	 21 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 president was
4 	 22 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 president unable <XB>
6 	 5 	 (NP\NP)/NP 	 2 	 Chugai of
6 	 8 	 (NP\NP)/(S[dcl]\NP) 	 1 	 Chugai which
6 	 9 	 ((S[dcl]\NP)/PP)/NP 	 1 	 Chugai spends <XB>
9 	 8 	 (NP\NP)/(S[dcl]\NP) 	 2 	 spends which
11 	 10 	 (N/N)/(N/N) 	 2 	 15 about
12 	 9 	 ((S[dcl]\NP)/PP)/NP 	 3 	 % spends
12 	 11 	 N/N 	 1 	 % 15
12 	 13 	 (NP\NP)/NP 	 1 	 % of
15 	 13 	 (NP\NP)/NP 	 2 	 sales of
15 	 14 	 NP[nb]/N 	 1 	 sales its
16 	 9 	 ((S[dcl]\NP)/PP)/NP 	 2 	 on spends
17 	 16 	 PP/NP 	 1 	 research on
19 	 16 	 PP/NP 	 1 	 development on
22 	 21 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 unable was
23 	 22 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to unable
24 	 23 	 (S[to]\NP)/(S[b]\NP) 	 2 	 pinpoint to
25 	 24 	 (S[b]\NP)/S[qem] 	 2 	 how pinpoint
26 	 25 	 ((S[qem]/(S[dcl]/NP))/N)/(S[adj]\NP) 	 3 	 much how
27 	 25 	 ((S[qem]/(S[dcl]/NP))/N)/(S[adj]\NP) 	 2 	 money how
28 	 29 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Chugai would
28 	 30 	 ((S[b]\NP)/PP)/NP 	 1 	 Chugai pump <XB>
29 	 25 	 ((S[qem]/(S[dcl]/NP))/N)/(S[adj]\NP) 	 1 	 would how
30 	 29 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 pump would
31 	 30 	 ((S[b]\NP)/PP)/NP 	 2 	 into pump
32 	 31 	 PP/NP 	 1 	 Gen-Probe into
<\s>
<s id="wsj_0404.20"> 27
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 We think
1 	 12 	 (S[dcl]\S[dcl])\NP 	 1 	 think said
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 Gen-Probe has
3 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 has think
4 	 3 	 (S[dcl]\NP)/NP 	 2 	 technology has
4 	 5 	 S[adj]\NP 	 1 	 technology important <XB>
5 	 6 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 2 	 important to
7 	 8 	 (NP[nb]/N)\NP 	 2 	 people 's
9 	 6 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 3 	 health to
9 	 8 	 (NP[nb]/N)\NP 	 1 	 health 's
11 	 12 	 (S[dcl]\S[dcl])\NP 	 2 	 he said
16 	 17 	 (S[dcl]\NP)/S[dcl] 	 1 	 We think
17 	 14 	 (S[ng]\NP)/S[dcl] 	 2 	 think adding
18 	 19 	 ((S[dcl]\NP[expl])/S[for])/(S[adj]\NP) 	 1 	 it is
19 	 17 	 (S[dcl]\NP)/S[dcl] 	 2 	 is think
20 	 19 	 ((S[dcl]\NP[expl])/S[for])/(S[adj]\NP) 	 3 	 important is
21 	 19 	 ((S[dcl]\NP[expl])/S[for])/(S[adj]\NP) 	 2 	 for is
22 	 21 	 (S[for]/(S[to]\NP))/NP 	 2 	 us for
22 	 24 	 (S[b]\NP)/NP 	 1 	 us have <XB>
23 	 21 	 (S[for]/(S[to]\NP))/NP 	 1 	 to for
24 	 23 	 (S[to]\NP)/(S[b]\NP) 	 2 	 have to
26 	 24 	 (S[b]\NP)/NP 	 2 	 technology have
26 	 25 	 NP/NP 	 1 	 technology such
<\s>
<s id="wsj_0404.21"> 28
0 	 4 	 (S[dcl]\NP)/S[em] 	 1 	 He emphasized
3 	 2 	 N/N 	 1 	 Bologna Mr.
3 	 4 	 (S[dcl]\NP)/S[em] 	 1 	 Bologna emphasized
5 	 4 	 (S[dcl]\NP)/S[em] 	 2 	 that emphasized
7 	 6 	 NP[nb]/N 	 1 	 companies both
7 	 8 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 companies would
7 	 9 	 (S[b]\NP)/NP 	 1 	 companies gain <XB>
8 	 5 	 S[em]/S[dcl] 	 1 	 would that
9 	 8 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 gain would
9 	 12 	 ((S\NP)\(S\NP))/NP 	 2 	 gain through
11 	 9 	 (S[b]\NP)/NP 	 2 	 knowledge gain
11 	 10 	 N/N 	 1 	 knowledge technological
14 	 12 	 ((S\NP)\(S\NP))/NP 	 3 	 sale through
14 	 13 	 NP[nb]/N 	 1 	 sale the
14 	 15 	 (NP\NP)/NP 	 1 	 sale of
16 	 15 	 (NP\NP)/NP 	 2 	 Gen-Probe of
16 	 18 	 (NP\NP)/(S[dcl]\NP) 	 1 	 Gen-Probe which
16 	 19 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Gen-Probe will <XB>
16 	 20 	 S[b]\NP 	 1 	 Gen-Probe expand <XB>
19 	 18 	 (NP\NP)/(S[dcl]\NP) 	 2 	 will which
20 	 19 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 expand will
20 	 21 	 (S\NP)\(S\NP) 	 2 	 expand significantly
20 	 22 	 ((S\NP)\(S\NP))/NP 	 2 	 expand as
24 	 22 	 ((S\NP)\(S\NP))/NP 	 3 	 result as
24 	 23 	 NP[nb]/N 	 1 	 result a
24 	 25 	 (NP\NP)/NP 	 1 	 result of
27 	 25 	 (NP\NP)/NP 	 2 	 acquisition of
27 	 26 	 NP[nb]/N 	 1 	 acquisition the
<\s>
<s id="wsj_0404.22"> 17
1 	 0 	 (S/S)/NP 	 2 	 1988 In
3 	 4 	 (S[dcl]\NP)/NP 	 1 	 Chugai had
4 	 0 	 (S/S)/NP 	 1 	 had In
4 	 11 	 ((S\NP)\(S\NP))/NP 	 2 	 had on
6 	 4 	 (S[dcl]\NP)/NP 	 2 	 income had
6 	 5 	 N/N 	 1 	 income net
6 	 7 	 (NP\NP)/NP 	 1 	 income of
8 	 7 	 (NP\NP)/NP 	 2 	 $ of
10 	 8 	 N/N[num] 	 1 	 million $
10 	 9 	 N/N 	 1 	 million 60
12 	 11 	 ((S\NP)\(S\NP))/NP 	 3 	 revenue on
12 	 13 	 (NP\NP)/NP 	 1 	 revenue of
14 	 13 	 (NP\NP)/NP 	 2 	 $ of
16 	 14 	 N/N[num] 	 1 	 million $
16 	 15 	 N/N 	 1 	 million 991
<\s>
<s id="wsj_0404.23"> 15
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 GenProbe had
1 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 had on
4 	 1 	 (S[dcl]\NP)/NP 	 2 	 loss had
4 	 2 	 NP[nb]/N 	 1 	 loss a
4 	 3 	 N/N 	 1 	 loss net
4 	 5 	 (NP\NP)/NP 	 1 	 loss of
6 	 5 	 (NP\NP)/NP 	 2 	 $ of
8 	 6 	 N/N[num] 	 1 	 million $
8 	 7 	 N/N 	 1 	 million 9.5
10 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 revenue on
10 	 11 	 (NP\NP)/NP 	 1 	 revenue of
12 	 11 	 (NP\NP)/NP 	 2 	 $ of
14 	 12 	 N/N[num] 	 1 	 million $
14 	 13 	 N/N 	 1 	 million 5.8
<\s>
<s id="wsj_0404.24"> 32
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 Gen-Probe received
3 	 0 	 S/S 	 1 	 received Recently
7 	 3 	 (S[dcl]\NP)/NP 	 2 	 patent received
7 	 4 	 NP[nb]/N 	 1 	 patent a
7 	 5 	 N/N 	 1 	 patent broad
7 	 6 	 N/N 	 1 	 patent U.S.
7 	 8 	 (NP\NP)/NP 	 1 	 patent for
10 	 8 	 (NP\NP)/NP 	 2 	 technology for
10 	 9 	 NP[nb]/N 	 1 	 technology a
10 	 11 	 (NP\NP)/(S[dcl]\NP) 	 1 	 technology that
10 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 technology helps <XB>
10 	 13 	 (S[b]\NP)/NP 	 1 	 technology detect <XB>
10 	 15 	 (S[b]\NP)/NP 	 1 	 technology identify <XU>
10 	 17 	 (S[b]\NP)/NP 	 1 	 technology quantify <XU>
12 	 11 	 (NP\NP)/(S[dcl]\NP) 	 2 	 helps that
13 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 detect helps
13 	 20 	 ((S\NP)\(S\NP))/NP 	 2 	 detect through
15 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 identify helps
15 	 20 	 ((S\NP)\(S\NP))/NP 	 2 	 identify through
17 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 quantify helps
17 	 20 	 ((S\NP)\(S\NP))/NP 	 2 	 quantify through
19 	 13 	 (S[b]\NP)/NP 	 2 	 organisms detect <XU>
19 	 15 	 (S[b]\NP)/NP 	 2 	 organisms identify <XU>
19 	 17 	 (S[b]\NP)/NP 	 2 	 organisms quantify
19 	 18 	 N/N 	 1 	 organisms non-viral
22 	 20 	 ((S\NP)\(S\NP))/NP 	 3 	 targeting through
22 	 21 	 NP[nb]/N 	 1 	 targeting the
22 	 23 	 (NP\NP)/NP 	 1 	 targeting of
25 	 23 	 (NP\NP)/NP 	 2 	 form of
25 	 24 	 NP[nb]/N 	 1 	 form a
25 	 26 	 (NP\NP)/NP 	 1 	 form of
28 	 26 	 (NP\NP)/NP 	 2 	 material of
28 	 27 	 N/N 	 1 	 material genetic
28 	 29 	 (S[pss]\NP)/NP 	 1 	 material called <XB>
31 	 29 	 (S[pss]\NP)/NP 	 2 	 RNA called
31 	 30 	 N/N 	 1 	 RNA ribosomal
<\s>
<s id="wsj_0404.25"> 27
2 	 0 	 (S/S)/NP 	 2 	 things Among
2 	 1 	 N/N 	 1 	 things other
5 	 4 	 N/N 	 1 	 Bologna Mr.
5 	 6 	 (S[dcl]\NP)/S[em] 	 1 	 Bologna said
6 	 0 	 (S/S)/NP 	 1 	 said Among
7 	 6 	 (S[dcl]\NP)/S[em] 	 2 	 that said
9 	 8 	 NP[nb]/N 	 1 	 sale the
9 	 10 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 sale will
9 	 11 	 (S[b]\NP)/NP 	 1 	 sale facilitate <XB>
10 	 7 	 S[em]/S[dcl] 	 1 	 will that
11 	 10 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 facilitate will
12 	 13 	 (NP[nb]/N)\NP 	 2 	 Gen-Probe 's
14 	 11 	 (S[b]\NP)/NP 	 2 	 marketing facilitate
14 	 13 	 (NP[nb]/N)\NP 	 1 	 marketing 's
14 	 15 	 (NP\NP)/NP 	 1 	 marketing of
18 	 15 	 (NP\NP)/NP 	 2 	 test of
18 	 16 	 NP[nb]/N 	 1 	 test a
18 	 17 	 N/N 	 1 	 test diagnostic
18 	 19 	 (NP\NP)/NP 	 1 	 test for
23 	 19 	 (NP\NP)/NP 	 2 	 syndrome for
23 	 20 	 N/N 	 1 	 syndrome acquired
23 	 21 	 N/N 	 1 	 syndrome immune
23 	 22 	 N/N 	 1 	 syndrome deficiency
26 	 19 	 (NP\NP)/NP 	 2 	 AIDS for
<\s>
<s id="wsj_0404.26"> 17
0 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Chugai will
0 	 3 	 (S[b]\NP)/NP 	 1 	 Chugai help <XB>
2 	 1 	 (S\NP)/(S\NP) 	 2 	 will also
2 	 16 	 (S[dcl]\S[dcl])\NP 	 1 	 will said
3 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 help will
3 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 help with
4 	 3 	 (S[b]\NP)/NP 	 2 	 Gen-Probe help
10 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 expertise with
10 	 6 	 NP[nb]/N 	 1 	 expertise its
10 	 7 	 N/N 	 1 	 expertise regulatory <XU>
10 	 9 	 N/N 	 1 	 expertise marketing
10 	 11 	 (NP\NP)/NP 	 1 	 expertise in
12 	 11 	 (NP\NP)/NP 	 2 	 Asia in
15 	 14 	 N/N 	 1 	 Bologna Mr.
15 	 16 	 (S[dcl]\S[dcl])\NP 	 2 	 Bologna said
<\s>
<s id="wsj_0404.27"> 17
2 	 0 	 NP[nb]/N 	 1 	 offer The
2 	 1 	 N/N 	 1 	 offer tender
2 	 3 	 (NP\NP)/NP 	 1 	 offer for
2 	 7 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 offer is
2 	 8 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 offer expected <XB>
2 	 10 	 S[b]\NP 	 1 	 offer begin <XB>
4 	 5 	 (NP[nb]/N)\NP 	 2 	 Gen-Probe 's
6 	 3 	 (NP\NP)/NP 	 2 	 shares for
6 	 5 	 (NP[nb]/N)\NP 	 1 	 shares 's
7 	 16 	 (S[dcl]\S[dcl])\NP 	 1 	 is said
8 	 7 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 expected is
9 	 8 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to expected
10 	 9 	 (S[to]\NP)/(S[b]\NP) 	 2 	 begin to
10 	 12 	 (S\NP)\(S\NP) 	 2 	 begin Monday
12 	 11 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 Monday next
15 	 14 	 NP[nb]/N 	 1 	 company the
15 	 16 	 (S[dcl]\S[dcl])\NP 	 2 	 company said
<\s>
